Advertisement

IgA Nephropathy - Clinical Features, Pathogenesis, and Treatment

  • Gerald B. Appel
Living reference work entry

Abstract

IgA Nephropathy is recogniszed as the most frequent form of glomerulonephritis worldwide. The disease is defined by the presence of IgA immune deposits in the glomereuli. Although the presentation is variable, the course is often one of insidous progression to end stage kidney disease with 15-20 % of patients reaching this point by 10 yrs and more with furhter follow. Recent studies have helped define which patients are high risk for progression using clinical and histopathologic features defined by a uniform pathology scoring system. Although much has recently been discovered about the pathogenesis of IgAN treatment studies have given conflicting results.

Keywords

IgA nephropathy Glomerular disease Henoch schoelein purpura Glomerulonephritis 

References

  1. Abe T, Kida H, Yoshimura M et al (1986) Participation of extracapillary lesions in the progression of IgA nephropathy. Clin Nephrol 25:37–41PubMedGoogle Scholar
  2. Akagi H, Kosaka M, Hattori K et al (2004) Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl 555:38CrossRefGoogle Scholar
  3. Almartine E, Sauron C, Laurent B et al (2011) The use of the Oxford classification to predict renal survival. Clin J Am Soc Nephrol 6:2384–2388CrossRefGoogle Scholar
  4. Ballardie FW (2004) IgA nephropathy treatment 25 years on: can we halt progression? The evidence base. Nephrol Dial Transplant 19:1041CrossRefPubMedGoogle Scholar
  5. Barratt J, Feehally J (2005) IgA nephropathy. J Am Soc Nephrol 16:2088–2097CrossRefPubMedGoogle Scholar
  6. Beaufils H, Jouanneau C, Katlama C et al (1995) HIV associated IgA nephropathy- a post mortem study. Nephrol Dial Transplant 10:35–38CrossRefPubMedGoogle Scholar
  7. Bennett WM, Walker RG, Kincaid Smith P (1989) Treatment of IgA nephropathy with eicosapentaenoic acid (EPA): a two year prospective trial. Clin Nephrol 31:128PubMedGoogle Scholar
  8. Berthoux F, Mohey H, Laurent B et al (2011) Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22:752–761CrossRefPubMedPubMedCentralGoogle Scholar
  9. Berthoux F, Suzuki H, Thibaudin L et al (2012) Autoantibodies targeting galactose 347:348. IgA associate with progressive IgA nephropathy. J Am Soc Nephrol 23:1579–1587CrossRefPubMedPubMedCentralGoogle Scholar
  10. Calvio-Rio …417 HSP pts in N Spain Med 93:106, (2014)Google Scholar
  11. Camilla R, Suzuki H, Dapra V, Loiacano E, Perruzi L, Amore A, Ghiggeri GM, Mazzucco G, Scolari F, Gharavi AG, Appel GB, Troyanov S, Novak J, Julian BA, Coppo R (2011) Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6:1903–1911CrossRefPubMedPubMedCentralGoogle Scholar
  12. Coppo R, Andrulli S, Amore A et al (2006) Predictors of outcome in HSP nephritis in children and adults. Am J Kidney Dis 47:993CrossRefPubMedGoogle Scholar
  13. Coppo R, Peruzzi L, Amore A et al (2007) IgACE: a placebo controlled randomized trial of ACE inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888CrossRefPubMedGoogle Scholar
  14. Coppo R, Toyanov S, Bellur S et al (2014) Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86:828–836CrossRefPubMedPubMedCentralGoogle Scholar
  15. Crowley-Nowick PA, Julian BA, Wyatt RJ et al (1991) IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. Kidney Int 39:1218–1224CrossRefPubMedGoogle Scholar
  16. Donadio JV, Grande JP (2002) IgA nephropathy. N Engl J Med 347:738CrossRefPubMedGoogle Scholar
  17. Donadio JV, Grande JP (2004) The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 24:225–243CrossRefPubMedGoogle Scholar
  18. Donadio JV, Bergstralh EJ, Offord KP et al (1994) A controlled trial of fish oil in IgA nephropathy: Mayo Nephrology Collaborative Group. N Engl J Med 331:1194CrossRefPubMedGoogle Scholar
  19. Donadio JV, Grande JP, Bergstralh EJ et al (1999) The long term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 10:1772PubMedGoogle Scholar
  20. Donadio JV, Bergstrahl EH, Grande JP, Rademcher DM (2002) Proteinuria patterns and their association with subsequent end stage renal disease in IgA nephropathy. Nephrol Dial Transplant 17:1197CrossRefPubMedGoogle Scholar
  21. Fellstrom BC, Barratt J, Cook H, et al (2017) NEFIGAN Trial Investigators: Targeted-release budesonide versus placebo in patients with IgAN: A double-blind randomized, placebo controlled phase 2b trial. Lancet 389:2117–2127Google Scholar
  22. Frisch G, Lin J, Rosenstock J, Markowitz G, D’Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel GB (2005) Mycophenolate mofetil vs placebo in patients with IgA nephropathy; a double blind, randomized, controlled trial. Nephrol Dial Transplant 20(10):2139–2145CrossRefPubMedGoogle Scholar
  23. Galla JH (1995) IgA nephropathy. Kidney Int 47:377CrossRefPubMedGoogle Scholar
  24. Geddes CC, Rauta V, Gronhagen-Riska C et al (2003) A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 18:1541CrossRefPubMedGoogle Scholar
  25. Gharavi A, Moldoveneau Z, Wyatt RJ et al (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19:1008–1014CrossRefPubMedPubMedCentralGoogle Scholar
  26. Gharavi A, Kiryluk K, Choi M et al (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321–327CrossRefPubMedPubMedCentralGoogle Scholar
  27. Haas M (1997) Histologic classification of IgA nephropathy: a study of 244 cases. Am J Kidney Dis 29:829–842CrossRefPubMedGoogle Scholar
  28. Haas M (2015) IgA nephropathy and Henoch Schonlein purpura nephritis. In: Jennette JC, D’Agati VD, Olson JL et al (eds) Heptinstall’s pathology of the kidney, 7th edn. Lippincott, Williams, and Wilkens, Philadelphia, pp 475–524Google Scholar
  29. Haas M, Ristaldi MP, Fervenza FC (2014) Histologic classification of glomerular diseases. Kidney Int 85:779–793CrossRefPubMedGoogle Scholar
  30. Hall CL, Bradley R, Kerr A et al (2004) Clinical value of renal biopsy in patients with asymptomatic hematuria with and without low grade proteinuria. Clin Nephrol 62:267CrossRefPubMedGoogle Scholar
  31. Herzenberg AM, Fogo AB, Reich HN et al (2011) Validation of the Oxford classification of IgA nephropathy. Kidney Int 80:310–317CrossRefPubMedGoogle Scholar
  32. Hogg RJ, Lee J, Nardelli N et al (2006) Clinical trial to evaluate omega 3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the SW pediatric study group. Clin J Am Soc Nephrol 1:467CrossRefPubMedGoogle Scholar
  33. Hotta O, Miyazaki M, Furuta T et al (2001) Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 38:736CrossRefPubMedGoogle Scholar
  34. Hou J-H, Wei-Bo L, Chen N, et al (2016) Mycophenolate mofetil combined with prednisone versus full dose prednisone in IgA Nephropathy with active proliferative lesions: A randomized controlled trial. Amer J Kidney Did 69:788–795Google Scholar
  35. Jennette JC, Falk RJ, Bacon PA et al (2013) Revised International Chapel Hill Classification of vascultitis. Arthritis and Rheum 65:1–11Google Scholar
  36. Kang Y, Park JS, Ha YJ et al (2014) Differences in Clinical manifestations and outcomes between adults and children with Henoch Schonlein Purpura. J Korean Med Sci 29:198–203Google Scholar
  37. Kawamura T, Yoshimura M, Miyazaki Y et al (2014) A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with IgA nephropathy. Nephrol Dial Transplant 29:1546CrossRefPubMedPubMedCentralGoogle Scholar
  38. Kidney Disease Improving Global Outcomes (KDIGO) (2012) Glomerulonephritis work group. Clinical practice guidelines for glomerulonephritis. Kidney Int 2:139–274CrossRefGoogle Scholar
  39. Kim CH, Lim BJ, Bae YS et al (2014) Using the Oxford Classification of IgA nephropathy to predeict long-term outocme of HSP nephritis in adults. Mod Pathol 27: 972–982Google Scholar
  40. Kiryluk K, Moldaveneau Z, Sanders JT et al (2011) Aberrant glycosylation of IgA 1 is inherited in both pediatric IgA nephropathy and Henoch Schonlein purpura nephritis. Kidney Int 80:79–87CrossRefPubMedPubMedCentralGoogle Scholar
  41. Kiryluk K, Li Y, Sana-Cherchi S et al (2012) Geographic differences in the genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8:e1002765CrossRefPubMedPubMedCentralGoogle Scholar
  42. Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196CrossRefPubMedPubMedCentralGoogle Scholar
  43. Komatsu H, Fujimoto S, Hara S et al (2008) Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 3:1301CrossRefPubMedPubMedCentralGoogle Scholar
  44. Lafayette RA, Canetta PA, Rovin BH et al (2017) A randomized controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:xxCrossRefGoogle Scholar
  45. Lai KN, Lai FM, Ho CP, Chan KW (1986) Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 26:174PubMedGoogle Scholar
  46. Le W, Liang SS, Hu YL et al (2011) Long term reanl survival and risk factors in IgA Nephropathy. Nephrol Dial Transplant 27:1479–1485Google Scholar
  47. Lee SM, Rao VM, Franklin WA et al (1982) IgA nephropathy: morphologic predictors of progressive renal disease. Human Pathol 13:314–322CrossRefGoogle Scholar
  48. Li LS, Liu ZH (2004) Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 66:920–923CrossRefPubMedGoogle Scholar
  49. Li PK-T, Leung CB, Chow KM et al (2006) Hong Kong study using valsartan in IgA nephropathy; a double blind randomized placebo controlled study. Am J Kidney Dis 47:751–760CrossRefPubMedGoogle Scholar
  50. Lv J, Xu D, Perkovic V et al (2012) Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23:1108CrossRefPubMedPubMedCentralGoogle Scholar
  51. Lv J, Shi S, Xu D et al (2013) Evaluation of the Oxford classification of IgA nephropathy; a systematic review and meta-analysis. Am J Kidney Dis 62:891–899CrossRefPubMedGoogle Scholar
  52. Lv J, Zhang H, Wong MG et al (2017) Testing Study Group: Effect of oral methylprednisolone on clinical outcomes in patients with IgAN: The TESTING randomized clinical trial. JAMA 318:432–442Google Scholar
  53. Maeda I, Hayashi T, Sato KK, Shibata MO, Hamada M, Kishida M, Kitabayashi C, Morikawa T, Okada N, Okumura M, Konishi M, Konishi Y, Endo G, Imanishi M (2012) Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant 27:2806–2813CrossRefPubMedGoogle Scholar
  54. Maes BD, Oyen R, Claes K et al (2004) Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842CrossRefPubMedGoogle Scholar
  55. Magistroni R, D’Agati VD, Appel GB, Kiryluk K (2015) New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 88:974–989CrossRefPubMedPubMedCentralGoogle Scholar
  56. Mann JF, Schmeider RE, McQueen M et al (2008) Renal outcomes with telmisartan, Ramipril, or both in people at high vascular risk (the ONTARGET study). Lancet 372:547CrossRefPubMedGoogle Scholar
  57. Manno C, Torres DD, Rossini M et al (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694CrossRefPubMedGoogle Scholar
  58. McQuarrie MP, Mackinnon B, Young B et al (2009) Centre variation in incidence, indication, and diagnosis of adult native renal biopsy in Scotland. Nephrol Dial Transplant 24:1524–1528CrossRefPubMedGoogle Scholar
  59. Mestecky J, Raska M, Julian BA et al (2013) IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol 8:217–240CrossRefPubMedGoogle Scholar
  60. Moldoveneaus Z, Wyatt RJ, Lee JY et al (2007) Patients with IgA nephropathy have increased serum galactose deficient IgA levels. Kidney Int 71:1148–1154CrossRefGoogle Scholar
  61. Mustonen J, Pasternack A, Rantala I (1983) The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 20:172PubMedGoogle Scholar
  62. Novack J, Julian BA, Tomana M et al (2008) IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 28:78–87CrossRefGoogle Scholar
  63. Pabst O (2012) New concepts in generation and function of IgA. Nat Rev Immunol 12:821–831CrossRefPubMedGoogle Scholar
  64. Pasternack A, Collin P, Mustonen J et al (1990) Glomerular IgA deposits in patients with celiac disease. Clin Nephrol 34:56–60PubMedGoogle Scholar
  65. Petterson EE, Rekola S, Berglund L et al (1994) Treatment of IgA nephropathy with omega 3 polyunsaturated fatty acids: a prospective, double blind, randomized study. Clin Nephrol 41:183Google Scholar
  66. Pillebout Thervet E, Hill G et al (2002) HSP in adults: outcome and prognostic factors. J Am Soc Nephrol 13:1271–1278CrossRefPubMedGoogle Scholar
  67. Pouria S, Feehally J (1999) Glomerular IgA deposition in liver disease. Nephrol Dial Transplant 14:2279–2282CrossRefPubMedGoogle Scholar
  68. Pozzi C, Bolasco PG, Fogazzi GB et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883CrossRefPubMedGoogle Scholar
  69. Pozzi C, Andrulli S, Del Vecchio L et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157CrossRefPubMedGoogle Scholar
  70. Pozzi C, Andrulli S, Pani A et al (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21:1783CrossRefPubMedPubMedCentralGoogle Scholar
  71. Praga M, Guttierrez E, Gonzalez E et al (2003) Treatment of IgA nephropathy with ACE inhibitors: a randomized controlled trial. J Am Soc Nephrol 14:1578–1583CrossRefPubMedGoogle Scholar
  72. Rasche FM, Schwartz A, Keller F (1999) Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 51:147PubMedGoogle Scholar
  73. Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225CrossRefPubMedGoogle Scholar
  74. Reich HN, Troyanov S, Scholey JW et al (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183CrossRefPubMedGoogle Scholar
  75. Rekola S, Bergstrand A, Bucht H (1991) Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 40:1050CrossRefPubMedGoogle Scholar
  76. Roberts IS (2014) Pathology of IgA nephropathy. Nat Rev Nephrol 10:445–454CrossRefPubMedGoogle Scholar
  77. Russo D, Pisani A, Balletta MM et al (1999) Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851–856CrossRefPubMedGoogle Scholar
  78. Shi SF, Wang SX, Jiang L et al (2011) Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the Oxford classification. Clin J Am Soc Nephrol 6:2175–2184CrossRefPubMedPubMedCentralGoogle Scholar
  79. Smerud HK, Bárány P, Lindström K et al (2011) New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 26:3237CrossRefPubMedGoogle Scholar
  80. Stripoli GF, Maione A, Schena FP, et al (2009) IgA Nephropathy: A disease in search of a large scale clinical trial. AJ Kidney Dis 53:5–8Google Scholar
  81. Strippoli GF, Manno C, Schena FP et al (2003) An evidence based survey of therapeutic options in IgA nephropathy. Am J Kidney Dis 41:1129CrossRefPubMedGoogle Scholar
  82. Sugiyama H, Yokoyama H, Sato H et al (2011) Japan renal biopsy registry: the first nationwide web based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol 15:493–503CrossRefPubMedGoogle Scholar
  83. Suzuki K, Honda K, Tanabe K et al (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63:2286–2294CrossRefPubMedGoogle Scholar
  84. Suzuki H, Fan R, Zhang Z et al (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG with restricted heterogeneity. J Clin Invest 119:1668–1677PubMedPubMedCentralGoogle Scholar
  85. Suzuki H, Kiryluk K, Novak J et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803CrossRefPubMedPubMedCentralGoogle Scholar
  86. Szeto CC, Lai FM, To KF et al (2001) The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 110:434CrossRefPubMedGoogle Scholar
  87. Tam FWK, Pusey CD (2018) TESTIN Corticaosteroids in IgA Nephropathy; A continuing challenge. Clin J Amer Soc Nephrol 13:158–160Google Scholar
  88. Tang Z, Wu Y, Wang QW et al (2002) Idiopathic IgA nephropathy with diffuse crescent formation. Am J Nephrol 22:480–486CrossRefPubMedGoogle Scholar
  89. Tang SC, Tang AW, Wong SS et al (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77:543CrossRefPubMedGoogle Scholar
  90. Tojo S, Hatano M, Honda M et al (1987) Natural history of IgA nephropathy in Japan. Semin Nephrol 7:386–388PubMedGoogle Scholar
  91. Topham PS, Harper SJ, Furness PN et al (1994) Glomerular disease as a cause of isolated microscopic hematuria. Q J Med 87:329PubMedGoogle Scholar
  92. Tumlin JA, Lohavichan V, Hennigar R (2003) Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 18:1321CrossRefPubMedGoogle Scholar
  93. Valentijn RM, Radl J, Haaijman JJ et al (1984) Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int 26:760–766CrossRefPubMedGoogle Scholar
  94. Vivante A, Afek A, Frenkel-Nir Y et al (2011) Persistent isolated microscopic hematuria in Israeli adolescents and young adults and risk for end stage renal disease. JAMA 306:729CrossRefPubMedGoogle Scholar
  95. Wakai K, Kawantura T, Endon M et al (2006) A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 21:2800CrossRefPubMedGoogle Scholar
  96. Walker RG, Yu SH, Owen JE, Kincaid-Smith P (1990) The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 34:103PubMedGoogle Scholar
  97. Wang Y, Chen J, Wang Y et al (2011) A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant 26:1923CrossRefPubMedGoogle Scholar
  98. Weiner NJ, Goodman JW, Kimmel PL (2003) The HIV associated renal disease: current insight into pathogenesis and treatment. Kidney Int 63:1618–1631CrossRefPubMedGoogle Scholar
  99. Westhoof T, Waldherr R, Loddenkemper C et al (2006) Mesangial i\IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease? Clin Nephrol 65:203CrossRefGoogle Scholar
  100. Woo KT, Lee GS, Lau YK et al (1991) Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 36:60PubMedGoogle Scholar
  101. Working Group of the IgANN, the Renal pathology Society, Coppo R et al (2010) The Oxford IgA nephropathy clinicopathologic classification is valid for children as well as adults. Kidney Int 77:921–927CrossRefGoogle Scholar
  102. Working Group of the International IgANN, the Renal Pathology Society, Roberts IS et al (2009) The Oxford classification of IgA nephropathy: pathology, definitions, correlations, and reproducibility. Kidney Int 76:546–556CrossRefGoogle Scholar
  103. Wyatt RJ, Julian BA (2013) IgA nephropathy. N Engl J Med 368:2402–2414CrossRefPubMedGoogle Scholar
  104. Xie Y, Chen X, Nishi S et al (2003) The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 63:1861CrossRefPubMedGoogle Scholar
  105. Yoshikawa N, Ito H, Sakai T et al (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese pediatric IgA nephropathy treatment study group. J Am Soc Nephrol 10:101PubMedGoogle Scholar
  106. Yoshikawa N, Honda M, Iijima K et al (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1:511CrossRefPubMedGoogle Scholar
  107. Zeng CH, Le W, Ni Z et al (2012) A multicenter application and evaluation of the Oxford classification of IgA nephropathy in adult Chinese patients. Am J kidney Dis 60:812–820CrossRefPubMedGoogle Scholar
  108. Zhao N, Hou P, Lv J et al (2012) The level of galactose deficient IgA in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790CrossRefPubMedPubMedCentralGoogle Scholar
  109. Zhou FD, Zhao MH, Zou WZ et al (2009) The changing spectrum of primary glomerular disease within 15 years: a survey of 3331 patients in a single Chinese center. Nephrol Dial Transplant 24:870876Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of MedicineColumbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations